TICKERNOMICS Sign up
Last Update: 2023-12-23 06:00:39
RAPT Therapeutics Inc. ( RAPT ) https://www.rapt.com
22.39USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
23.45%
RAPT
30.48%
SPY
30.72%
-1.02%
RAPT
SPY
112.82%
RAPT
0.00%
SPY
201.04%
RAPT
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
755.65
632.47
0.77
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-7.19
258.43
4.37
-9.48
0.00
-5.40
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-4923.87
100.00
-4568.29
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
3.86
-327.35
-57.94
0.00
Other Earnings and Cash Flow Stats:
RAPT Therapeutics Inc. ( RAPT ) Net Income TTM ($MM) is -100.61
RAPT Therapeutics Inc. ( RAPT ) Operating Income TTM ($MM) is -111.59
RAPT Therapeutics Inc. ( RAPT ) Owners' Earnings Annual ($MM) is 0.00
RAPT Therapeutics Inc. ( RAPT ) Current Price to Owners' Earnings ratio is 0.00
RAPT Therapeutics Inc. ( RAPT ) EBITDA TTM ($MM) is -110.45
RAPT Therapeutics Inc. ( RAPT ) EBITDA Margin is -4568.29%
Capital Allocation:
RAPT Therapeutics Inc. ( RAPT ) has paid 0.00 dividends per share and bought back -4.673771 million shares in the past 12 months
RAPT Therapeutics Inc. ( RAPT ) has reduced its debt by 0.405 million USD in the last 12 months
Capital Structure:
RAPT Therapeutics Inc. ( RAPT ) Interest-bearing Debt ($MM) as of last quarter is 7
RAPT Therapeutics Inc. ( RAPT ) Annual Working Capital Investments ($MM) are 44
RAPT Therapeutics Inc. ( RAPT ) Book Value ($MM) as of last quarter is 172
RAPT Therapeutics Inc. ( RAPT ) Debt/Capital as of last quarter is 4%
Other Balance Sheet Stats:
RAPT Therapeutics Inc. ( RAPT ) has 54 million in cash on hand as of last quarter
RAPT Therapeutics Inc. ( RAPT ) has 21 million of liabilities due within 12 months, and long term debt 0 as of last quarter
RAPT Therapeutics Inc. ( RAPT ) has 38 common shares outstanding as of last quarter
RAPT Therapeutics Inc. ( RAPT ) has 0 million USD of preferred stock value
Academic Scores:
RAPT Therapeutics Inc. ( RAPT ) Altman Z-Score is 12.71 as of last quarter
RAPT Therapeutics Inc. ( RAPT ) Piotroski Score is 2.00 as of last quarter
Corporate Governance:
RAPT Therapeutics Inc. ( RAPT ) largest shareholder is owning shares at 0.00 ($MM) value
William Ho(an insider) Sold 1500 shares of RAPT Therapeutics Inc. ( RAPT ) for the amount of $20580.00 on 2023-11-28
1.89% of RAPT Therapeutics Inc. ( RAPT ) is held by insiders, and 105.47% is held by institutions
RAPT Therapeutics Inc. ( RAPT ) went public on 2019-10-31
Other RAPT Therapeutics Inc. ( RAPT ) financial metrics:
FCF:-81.44
Unlevered Free Cash Flow:0.00
EPS:-3.27
Operating Margin:-4923.87
Gross Profit Margin:100.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-72.62
Beta:0.00
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About RAPT Therapeutics Inc. ( RAPT ) :
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. The company's lead oncology drug candidate is FLX475, an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. It also focuses on the development of hematopoietic progenitor kinase 1 inhibitor. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.